Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin plus Hexintong oral solution vs rosuvastatin alone in dyslipidemia with elevated lipoprotein(a)
ChiCTR2200057751Phase 4Recruiting
- Sponsor
- Ben'gang General Hospital
- Start
- Mar 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of rosuvastatin and hexintong in dyslipidemia and hyperlipidemia (2 arms), sponsored by Ben'gang General Hospital. Primary endpoint: Change in lipoprotein(a) levels before and after treatment. Started Mar 2022; status: recruiting.
02
Drugs
rosuvastatinhexintong
03
Conditions
dyslipidemiahyperlipidemia
Beyond the preview
Go deeper on ChiCTR2200057751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057751.